Business

Sanara MedTech to Present at the 2021 Cantor Virtual Global Healthcare Conference

FORT WORTH, TX / ACCESSWIRE / September 22, 2021 / Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us")

articleSanara Medtech Inc.September 22, 20213/company/sanara-medtech-inc/news/sanara-medtech-to-present-at-the-2021-cantor-virtual-global-healthcare-conference
Sanara MedTech to Present at the 2021 Cantor Virtual Global Healthcare Conference

About this update from Sanara Medtech Inc.

[{"type":"text","content":"FORT WORTH, TX / ACCESSWIRE / September 22, 2021 / Based in Fort Worth, Texas, Sanara MedTech Inc. (\"Sanara,\" the \"Company,\" \"we,\" \"our\" or \"us\") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that the Company is scheduled to present virtually at the 2021 Cantor Virtual Global Healthcare Conference. Sanara's presentation will be given on Wednesday, September 29, 2021 at 9:20 a.m. ET.The presentation materials for the conference will be posted to the Investor Relation's section of the Company's website, www.SanaraMedTech.com, prior to the conference.About Sanara MedTech Inc.With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes, and develops wound and skincare products for use by physicians and clinicians in hospitals, clinics, and all post-acute care settings and has begun offering wound care and dermatology virtual consultation services via telemedicine. Sanara's products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen® to the surgical markets as well as the following products to the wound care market: BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution and HYCOL™ Hydrolyzed Collagen. Sanara's pipeline contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, and cell compatible substrates. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skincare for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry. For more information, visit www.SanaraMedTech.com.Information about Forward-Looking StatementsThe statements in this press release that do not constitut...

More updates from Sanara Medtech Inc.